European Journal of Clinical Pharmacology
Overview
The European Journal of Clinical Pharmacology is a renowned scientific journal that publishes original research articles, reviews, and case reports in the field of clinical pharmacology. It covers a wide range of topics including drug interactions, pharmacokinetics, adverse drug reactions, and therapeutic drug monitoring. The journal aims to provide valuable insights into the safe and effective use of medications, promoting evidence-based clinical practice and improving patient outcomes.
Details
Details
Abbr.
Eur J Clin Pharmacol
Start
1970
End
Continuing
Frequency
Twelve no. a year
p-ISSN
0031-6970
e-ISSN
1432-1041
Country
Germany
Language
English
Specialty
Pharmacology
Metrics
Metrics
h-index / Ranks: 2146
123
SJR / Ranks: 6040
727
CiteScore / Ranks: 5069
5.00
JIF / Ranks: 3624
2.9
Recent Articles
1.
Alqawasmeh K, Mason T, Morris A, Hafez W, Hasan T, Taher S, et al.
Eur J Clin Pharmacol
. 2025 Mar;
PMID: 40085198
Background: The adoption of generic and biosimilar medications is crucial for improving healthcare accessibility and cost savings in the Middle East and North Africa (MENA) region. Understanding the factors that...
2.
Ozpolat C, Okcay Y, Ulusoy K, Yildiz O
Eur J Clin Pharmacol
. 2025 Mar;
PMID: 40080139
Purpose: Placebo is a term to define physiologically inactive compounds used in treatment that causes physical and emotional changes. The placebo effect, driven by expectation and conditioning, plays a significant...
3.
Sharma R, Gulati A, Chopra K
Eur J Clin Pharmacol
. 2025 Mar;
PMID: 40080138
Purpose: The regulatory landscape in rare diseases and oncology has evolved to address unmet medical needs by implementing expedited approval pathways. The US FDA's Accelerated Approval and the EMA's Conditional...
4.
Jiang K, Liu M, Zhao X, Wang S, Ling Y, Qiao L, et al.
Eur J Clin Pharmacol
. 2025 Mar;
PMID: 40080137
Purpose: Overall survival (OS) is recommended as a gold standard endpoint but has some limitations. We aimed to finding more effective surrogate endpoints for advanced hepatocellular carcinoma (HCC) treated with...
5.
Fors A, Forslund T, Sundstrom A, Wettermark B
Eur J Clin Pharmacol
. 2025 Mar;
PMID: 40074942
Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained considerable media attention, but there is limited knowledge about those receiving the drugs. This study aimed to assess demographic characteristics and...
6.
Houwen J, Lalmohamed A, Zwaan J, Egberts T, Duyvendak M, Fiolet A, et al.
Eur J Clin Pharmacol
. 2025 Mar;
PMID: 40053073
Background: Low-dose (0.5 mg/day) colchicine improves cardiovascular outcomes in patients with stable coronary disease. Around 10-15% of these patients simultaneously use anticoagulant therapy, including vitamin-K antagonists (VKAs). In vitro studies...
7.
Bourgeois J, Costa E, Devos C, Luyten J, Ombelet S, Thiry N, et al.
Eur J Clin Pharmacol
. 2025 Feb;
PMID: 40019504
Purpose: Although already a lot of research has been done on pharmacogenetic tests to inform the choice and/or dosing of medicines, the implementation and clinical uptake remain limited. This study...
8.
Saint-Lary L, Beau A, Sommet A, Leroy V, Loane M, Cavero-Carbonell C, et al.
Eur J Clin Pharmacol
. 2025 Feb;
PMID: 40011239
Purpose: Antiretroviral drugs are recommended during pregnancy to achieve HIV viral suppression and reduce mother-to-child transmission. Congenital anomaly signals were reported after fetal exposure to antiretroviral drugs in several studies...
9.
Kruse M, Stankeviciute S, Perry S
Eur J Clin Pharmacol
. 2025 Feb;
PMID: 40000475
Every drug development is a complex and long journey. Clinical pharmacology is an essential discipline in modern drug development. With its applications, computational modelling, and simulation techniques, it can significantly...
10.
Jang J, Jeong S
Eur J Clin Pharmacol
. 2025 Feb;
PMID: 40000474
Background: Bioequivalence assessment determines the equivalence between drug formulations and is primarily used to demonstrate that a generic product is equivalent to its reference. The sex of the drug consumer...